Trial · NCT05691257
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in the hemoglobin from baseline | up to 8 week | Hemoglobin is calculated by the routine blood test |
| Secondary | Change in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) | Up to 8 weeks | Change from baseline to week 12 in N-terminal pro-brain natriuretic peptide (NT-proBNP). Baseline value was defined as the mean of all available measurements from the screening visit until start of treatment with randomised study medication. |
| Secondary | Change in Left Ventricular Systolic Function | Up to 24 weeks | Change in left ventricular ejection fraction is assessed by two-dimensional directed M-mode echocardiography |
| Secondary | Change in Left Ventricular End-Diastolic Diameter | Up to 24 weeks | Change in left ventricular end-diastolic diameter is assessed by two-dimensional directed M-mode echocardiography |
| Secondary | Change in Left Ventricular Diastolic Function | Up to 24 weeks | Change in E/e' is assessed by two-dimensional directed M-mode echocardiography |
| Secondary | Change in Low-density lipoprotein（LDL） | Up to 8 weeks | Change from baseline to week 8 in Low-density lipoprotein（LDL）.Baseline value was defined as the mean of all available measurements from the screening visit until start of treatment with randomised study medication. |
| Secondary | Change in Serum ferritin | Up to 8 weeks | Change from baseline to week 8 in Serum ferritin.Baseline value was defined as the mean of all available measurements from the screening visit until start of treatment with randomised study medication. |
| Secondary | Change in Transferrin saturation | Up to 8 weeks | Change from baseline to week 8 in Transferrin saturation.Baseline value was defined as the mean of all available measurements from the screening visit until start of treatment with randomised study medication. |
| Secondary | Change in Left atrial volume | Up to 24 weeks | Change in left atrial volume is assessed by two-dimensional directed M-mode echocardiography |
| Secondary | Change in Left atrial volume index | Up to 24 weeks | Change in left atrial volume index is assessed by two-dimensional directed M-mode echocardiography |
| Other | Liver Injury | Up to 8 weeks | Liver injury is defined as: i) a rise of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) to 3 times above the upper limit of normal \[ULN\], or ii) a rise of total bilirubin to 2 times above the upper limit of normal \[ULN\] |
| Other | Hyperkalemia | Up to 8 weeks | Hyperkalemia is defined as：Serum potassium \> 5.5 mmol/L |
| Other | Thromboembolism | Up to 1 year | Thromboembolism is defined as：Deep vein thrombosis at follow-up |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05691257/registered